ClinicalTrials.gg
RecruitingNCT07196657Updated Feb 11, 2026

The Efficacy and Safety of Pregabalin and Crisugabalin in Patients With Fibromyalgia

An interventional study of Pregabalin and Crisugabalin in Fibromyalgia, Pregabalin and Pain, sponsored by Beijing Tiantan Hospital. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-02-11.

Sponsored by Beijing Tiantan Hospital · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Sep 2025; still recruiting 1 year 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
1,116
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 29 studies in Fibromyalgia with a site in China — 14 open to participants now, 14 under way, none of them phase 3. Fibromyalgia · China.

Planned enrollment
Largest of 23
1,116 · median 120
Started
2025
with 9 others
No phase
19 of 29
10 open now
Primary completion
2027-06
later than 3 of 13 live
Registered
21st of 29
by date
Lead sponsor
8 of 29
Beijing Tiantan Hospital

Among the 29 studies in Fibromyalgia with a site in China, this one has the largest planned enrollment of the 23 interventional ones that give a count, is one of 10 that started in 2025, is one of 19 with no phase, reaches primary completion later than 3 of the 13 other live ones, and was the 21st registered.

Fibromyalgia

1,245 studies on the registry are indexed under Fibromyalgia; 256 are open to participants now.

Browse Fibromyalgia studies →

Open to participants now

14 of the 29 studies in Fibromyalgia with a site in China are open now. Recruiting first, the newest first:

8 more — sign in →

All 14 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 161 Fibromyalgia studies recruiting now, 51 (32%) set no upper age limit and 96 (60%) stop at 75 or younger; 15 take children under 18; 35 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 29 studies in Fibromyalgia with a site in China, or all of them as a file.
02

Study summary

Fibromyalgia (FM) is a chronic pain syndrome characterized by widespread pain, fatigue, and emotional disorders. Its onset is related to factors such as central sensitization and imbalance of neurotransmitters. The current mainstream treatments include pregabalin, but the efficacy of pregabalin is limited, with only 25%-40% pain relief rate, and adverse reactions are common. crisugabalin, a new highly selective α2δ ligand, has shown potential in animal models or preliminary clinical trials, but there is insufficient evidence for its application in FM. This study aims to explore the effectiveness and safety of pregabalin or crisugabalin in treating FM, with the aim of providing a better treatment option for FM patients.

03

Conditions studied

  • Fibromyalgia
  • Pregabalin
  • Pain
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosed with FM according to the 2016 Revisions to the 2010/2011 FM diagnostic criteria;
  • Aged over 18 years old;
  • Suffering from moderate to severe FM, to non-pharmacological interventions and without prior exposure to recommend pharmacological treatments for FM;
  • Baseline numeric rating scale (NRS) score of 4 or higher;
  • and alanine aminotransferase levels below twice the ;
  • Estimated (eGFR) of at least 30 mL/min/1.73 m²;
  • Willingness to provide and adequate cognitive and language capabilities to meet all study requirements;

Exclusion criteria

Exclusion Criteria:

  • Previous allergic reactions to pregabalin, crisugabalin, or any of their ;
  • Prior diagnosis of epilepsy or depression requiring antidepressant therapy;
  • Women who are pregnant or breastfeeding;
  • Has severe systemic illnesses, such as poorly controlled hypertension, poorly controlled diabetes mellitus, or significant cardiac impairment;
  • Suffering from acute or chronic pain disorders other than FM.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
1,116 participants (estimated)

Study arms

  • Active comparator
    Pregabalin group

    Drug: Pregabalin

  • Experimental
    Crisugabalin group

    Drug: Crisugabalin

Interventions

  • For the pregabalin group, treatment will be initiated at a dosage of 150 mg daily, administered into 2 or 3 divided doses. After 3 to 7 days, the dose will be titrated to 300 mg per day, with subsequent incremental increases of 150 mg daily permitted at 3-day to 7-day intervals based on therapeutic response and tolerability, up to a maximum dose of 450 mg daily.

  • For the crisugabalin group, therapy will begin at 20 mg twice daily, with a maximum allowable dose of 40 mg twice daily.

06

What researchers measure

Primary outcomes

  1. The proportion of patients achieving pain relief

    The proportion of patients achieving pain relief defined as the proportion of patients whose baseline average pain intensity is reduced by at least 50%. The pain intensity will be measured based on NRS, where 0 represents no pain and 10 represents worst pain imaginable.

    Time frame: At the 12-weeks

Secondary outcomes

  1. The average pain intensity

    The average pain intensity. The pain intensity will be measured based on NRS, where 0 represents no pain and 10 represents worst pain imaginable.

    Time frame: At the weeks 1, 2, 4, 8, and 12

  2. The worst pain intensity

    The worst pain intensity. The pain intensity will be measured based on NRS, where 0 represents no pain and 10 represents worst pain imaginable.

    Time frame: At the weeks 1, 2, 4, 8, and 12

  3. Dose of crisugabalin or pregabalin

    the dose of experimental drug

    Time frame: At the week 1, 2, 4, 8, 12

  4. Average weekly consumption of rescue analgesics

    Acetaminophen will be permitted as rescue medication for FM-related pain, at doses up to 1000 mg per administration and not exceeding 3000 mg per day. All rescue medication use, including dose and frequency, will be recorded prospectively.

    Time frame: at weeks 4, 8, 12

  5. The Revised FM Impact Questionnaire

    The Revised FM Impact Questionnaire is a 21-item self-administered questionnaire, based on symptoms reported within the preceding 7 days. The total score ranges from 0 to 100, with higher values indicating worse health status.

    Time frame: At the weeks 4, 8, and 12

  6. The Brief Pain Inventory (BPI) severity (BPI-S) and interfere (BPI-I) subsc

    The BPI-S assesses pain intensity over the past 24 hours, including 4 items. The BPI-I evaluates the degree to which pain interferes with daily activities, comprising 7 items. Each BPI item is rated on a 0 to 10 NRS, with 0 represents no pain or does not interfere, and 10 represents worst pain imaginable or interferes completely. Higher scores indicate greater pain severity or interfere.

    Time frame: At the weeks 4, 8, and 12

  7. The short-form 36 Health Survey (SF-36)

    The SF-36 assesses health-related quality of life, capturing preferences across various health states. It assesses 8 dimensions: physical functioning, physical role limitations due to physical health, bodily pain, general health, vitality, social functioning, emotional role limitations due to emotional problems, and mental health. Scores range from 0 to 100 for each dimension, with higher scores indicating better health status.

    Time frame: At the weeks 4, 8, and 12

  8. Patient Global Impression of Change Scale

    A 7-point patient-reported Likert scale for evaluating subjective overall change in health/symptoms from baseline, used to assess treatment efficacy in clinical research and practice.

    Time frame: at week 12

  9. The Medical Outcomes Study Sleep Scale (MOS)

    The MOS uses a 6-point scale to evaluate various dimensions of sleep, consisting of 12 items. A score of 1 indicates persistent presence, with a score of 6 denotes complete absence.

    Time frame: At the weeks 4, 8, and 12

  10. The Beck Depression Inventory-Ⅱ (BD-Ⅱ)

    The BD-Ⅱ employs a 4-point scale (ranging from 0 to 3) to evaluate the severity of depressive symptoms, comprising 21 items in total. A score of 0 indicates the absence of symptoms, while a score of 3 reflects severe symptomatology.

    Time frame: At the weeks 4, 8, and 12

  11. Adverse Events

    Adverse Events are defined as events that occur the course of treatment, were not present before prior to the intervention, or represent a worsening of pre-existing conditions. These events will be systematically documented and categorized by severity into grades such as mild, moderate, severe, or life-threatening.

    Time frame: Through study completion, an average of 12 weeks

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Liu M, Li R, Zhou H, Xie Z, He Y, Ren F, Feng X, Fan B, Li S, Luo F, Zhang D. The Efficacy and Safety of Crisugabalin (HSK16149) in Fibromyalgia Patients: Protocol for a Prospective Randomized Open Blinded-Endpoint (PROBE) Study. J Pain Res. 2026 Mar 3;19:580694. doi: 10.2147/JPR.S580694. eCollection 2026. PubMed 41800444 ↗

Related links

Individual participant data

Plan to share: Yes — Individual participant data that underlie the results reported in this article, after de-identification (text, tables, figures and appendices) are available. Derived data supporting the findings of this study are available from the corresponding author Fang Luo on request.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2025 (actual). Primary completion is estimated for Jun 2027, 21 months after the start.

Of 439 non-industry interventional studies with no phase under Fibromyalgia, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 31. This study's planned 21 months is above that.

Counting every sponsor, half of 452 studies reached it within 15 months; a quarter within 6 and three quarters within 31.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 20, 2025
First posted
Sep 29, 2025
StartActual
Sep 30, 2025
Primary completionEst.
Jun 30, 2027
CompletionEst.
Aug 31, 2027
Last update
Feb 11, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 11, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07196657
Collaborators
China-Japan Friendship Hospital, The First Affiliated Hospital of Nanchang University, Peking University Third Hospital, The Fourth Affiliated Hospital of Harbin Medical University, Zhongnan Hospital, Xiangya Hospital of Central South University, The Affiliated Hospital of Yanbian University, The Second Hospital University of South China, LanZhou University
Responsible party
Fang Luo (Director, Department of Pain Management, Principal Investigator, Clinical Professor, Beijing Tiantan Hospital) — Principal investigator
First posted
Sep 29, 2025
Start date
Sep 30, 2025
Primary completion
Jun 30, 2027 (estimated)
Completion
Aug 31, 2027 (estimated)
Last update
Feb 11, 2026

Study contacts

Fang Luo, M.D.
Contact
13611326978@163.com
+86 13611326978

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Crisugabalin

Start the discussion